Comparative Pharmacology
Head-to-head clinical analysis: AMTURNIDE versus METATENSIN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMTURNIDE versus METATENSIN 4.
AMTURNIDE vs METATENSIN #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine transporter (VMAT), reducing sympathetic outflow. Hydralazine directly relaxes arteriolar smooth muscle by increasing cGMP levels. Hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
10 mg to 20 mg orally once daily, with or without food.
2 tablets sublingually every 4 hours as needed for angina. Each tablet contains nitroglycerin 0.6 mg.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
12-18 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
Renal (70% unchanged, 20% as metabolites); biliary/fecal (10%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination